Enduring Material

The training is an Enduring Material consisting of a structured self-paced curriculum. It utilizes a mix of literature review, evidence-based clinical guidelines, visual flow charts (e.g., the 5As Patient Flow Chart), and example scripts for patient-centered communication.

• Understand the potential harms related to perinatal cannabis use.
• Identify current guidelines for prenatal and postnatal cannabis use.
• Locate and utilize screening assessment tools for perinatal cannabis use.
• Develop knowledge on available evidence-based treatments for perinatal cannabis use.
• Develop skills to increase self-efficacy and intent to manage perinatal cannabis use.
• Locate local and national resources for perinatal cannabis use.

• The Colorado Medical Society designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
• The Colorado Medical Society designates this enduring material for a maximum of 2 Hour(s) Attendance w/ No Credit. Participants should claim only the credit commensurate with the extent of their participation in the activity.

This training aims to provide educational materials and best practice guidelines to support healthcare providers to identify and manage (i.e., treat or refer to care) perinatal cannabis use among pregnant and postpartum women. This training provides an overview of the risks of perinatal cannabis use on numerous maternal and child outcomes. It is based on the latest research and the current recommendations from leading governing bodies on cannabis use during pregnancy and the postpartum period. It will also enhance patient-provider communication using the 5As framework (i.e., Ask, Advise, Agree, Assist and Arrange) to guide providers to assess for perinatal cannabis use, advise the patient on the health risks and available treatment options, agree on a treatment plan, assist the patient in any problem solving related to obtaining treatment, and arrange for supports for the patient. Providers will learn how to communicate the current national guidelines, safety considerations, and employ brief counseling strategies related to perinatal cannabis use.

Sarah Gelinas, MPH has no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients to disclose.

80 %

100 %

5/1/2026